GLP1R and inflammatory bowel disease: Reduction of GLP-1 receptor agonist activity has been shown to exert multiple anti-inflammatory effects in conditions like diabetes, neurodegenerative diseases, as Parkinson’s disease, and inflammatory bowel diseases [38].